How to Get Jardiance in New Mexico: Prescriptions, Telehealth, and Pharmacy Options

What Is Jardiance and Why Are New Mexico Patients Seeking It?

Jardiance is FDA-approved empagliflozin, an SGLT2 inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood sugar, blood pressure, and intraglomerular pressure simultaneously. New Mexico has one of the highest rates of type 2 diabetes in the United States. According to CDC surveillance data, approximately 11.1% of New Mexico adults have diagnosed diabetes, compared with the national average of 8.8% [1]. That burden, combined with high rates of diabetic kidney disease and heart failure in the state, has driven sharp demand for SGLT2 inhibitors like empagliflozin.

The landmark EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) in patients with established cardiovascular disease [2]. Cardiovascular death alone fell by 38% relative to placebo [2]. Those numbers explain why cardiologists, nephrologists, and primary care providers across New Mexico have added empagliflozin to standard-of-care regimens.

The FDA has granted empagliflozin three distinct approvals: type 2 diabetes mellitus (2014), heart failure with reduced ejection fraction (2021), and chronic kidney disease (2023), as documented in the Jardiance prescribing information [3]. Each indication carries its own dosing and eGFR threshold requirements.

Who Can Prescribe Jardiance in New Mexico?

Any licensed prescriber in New Mexico may write a Jardiance prescription, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). New Mexico is a full-practice-authority state for NPs, meaning nurse practitioners may prescribe Schedule II through V controlled substances and non-controlled medications without a physician collaboration agreement [4]. PAs in New Mexico prescribe under a supervision agreement but may independently initiate empagliflozin after appropriate evaluation.

Telehealth providers licensed in New Mexico may also prescribe Jardiance. The New Mexico Telehealth Act (NMSA 1978, Section 24-25-1 et seq.) allows synchronous video encounters to satisfy the prescribing relationship requirement for non-controlled medications [5]. Empagliflozin is not a controlled substance, so a telehealth visit alone, without a prior in-person examination, legally supports a new prescription in this state.

The HealthRX prescribing framework for telehealth-initiated empagliflozin in New Mexico follows four steps: (1) synchronous video intake covering cardiovascular history, kidney function, and current medications; (2) remote lab order for eGFR, BMP, and HbA1c sent to a patient-convenient draw site; (3) clinical review of results within 24 to 48 hours; and (4) e-prescription sent to the patient's preferred pharmacy. Patients with an eGFR <20 mL/min/1.73m² for the CKD indication or <30 mL/min/1.73m² for the diabetes indication are not candidates under FDA labeling [3].

What Labs Are Required Before Starting Jardiance in New Mexico?

Before any provider, telehealth or in-person, issues a Jardiance prescription, a minimum lab panel must be reviewed. The American Diabetes Association Standards of Medical Care in Diabetes 2024 specify that eGFR and urine albumin-to-creatinine ratio (UACR) should be assessed before initiating an SGLT2 inhibitor and at least annually thereafter [6]. Specific required values include:

A basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) documents serum creatinine, electrolytes, and blood glucose. The eGFR derived from serum creatinine determines which indication applies and whether the drug is contraindicated. An HbA1c is required for the type 2 diabetes indication to confirm diagnosis and establish a treatment baseline. A urinalysis or UACR quantifies albuminuria, which is a key criterion for the CKD indication per the EMPA-KIDNEY trial protocol (N=6,609) [7]. Complete blood count is optional but recommended in patients with suspected anemia prior to starting therapy.

The EMPA-KIDNEY trial, published in the New England Journal of Medicine in 2023, showed that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% (hazard ratio 0.72; 95% CI 0.64 to 0.82; P<0.001) in patients with CKD across a wide eGFR range of 20 to 45 mL/min/1.73m² [7]. This trial included patients without diabetes, broadening the prescribing rationale substantially.

LabCorp, Quest Diagnostics, and Presbyterian Healthcare draw stations throughout Albuquerque, Santa Fe, Las Cruces, and Roswell accept electronic lab orders from out-of-state or telehealth providers, meaning remote prescribers can order labs before the patient ever steps into a local clinic.

How Does Telehealth Jardiance Prescribing Work in New Mexico?

New Mexico telehealth law permits a prescribing relationship to be established via synchronous video for non-controlled medications [5]. Empagliflozin qualifies. The practical sequence for a patient in, say, Taos or Gallup without local endocrinology access is straightforward.

First, the patient schedules a video visit with a telehealth provider licensed in New Mexico. Second, lab orders are transmitted electronically to the nearest draw site. Third, once results return (typically 24 to 72 hours), the provider reviews them and either approves or modifies the plan. Fourth, an e-prescription is sent to the patient's local pharmacy or a mail-order pharmacy licensed to ship to New Mexico. The entire process from first video visit to having the medication in hand commonly takes 3 to 7 days, depending on lab turnaround and pharmacy inventory.

Asynchronous (store-and-forward) encounters may not legally satisfy the initial prescribing relationship requirement in New Mexico for a new controlled or non-controlled prescription without a prior established relationship [5]. Patients should confirm that their telehealth platform uses live video for the initial visit.

The FDA's guidance on telemedicine prescribing practices notes that for non-controlled drugs, states may set their own standards, and New Mexico's current standards permit the telehealth model described above [8].

Insurance Coverage, Prior Authorization, and Costs in New Mexico

Commercial insurance coverage for Jardiance in New Mexico generally requires prior authorization (PA). The PA process typically demands documented HbA1c above 7.0% for the diabetes indication, an eGFR report, evidence of metformin trial or contraindication, and confirmation of cardiovascular risk factors or established cardiovascular disease. Some plans also require documentation of a failed trial of a less expensive agent, such as metformin or a sulfonylurea [9].

New Mexico Medicaid (Centennial Care) does not currently list empagliflozin on its preferred drug list for type 2 diabetes as of the 2025 formulary. The New Mexico Human Services Department Medicaid program covers some SGLT2 inhibitors under the heart failure indication for patients meeting strict criteria, but coverage is not guaranteed and varies by managed care organization [10]. Patients should contact their specific Medicaid plan (Molina, Presbyterian Centennial, United Healthcare Community Plan) to confirm current formulary status.

For uninsured patients, Boehringer Ingelheim and Eli Lilly offer the Jardiance Savings Card program, which may reduce out-of-pocket cost to as low as $10 per 30-day supply for commercially insured patients, though the program excludes government-funded insurance [11]. GoodRx pricing at New Mexico pharmacies lists 30 tablets of empagliflozin 10 mg at approximately $530 to $560 without insurance as of mid-2025.

The American Heart Association's 2022 Heart Failure Guideline gave empagliflozin a Class I recommendation (Level of Evidence A) for patients with HFrEF to reduce hospitalization and cardiovascular death, regardless of diabetes status [12]. That classification strengthens PA appeals for the heart failure indication significantly.

As the AHA/ACC guideline states directly: "In patients with symptomatic chronic HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for HF and cardiovascular death" [12]. Quoting this language in a PA appeal letter often accelerates insurer review.

Pharmacies in New Mexico That Dispense Jardiance

Major retail chains across New Mexico, including Walgreens, CVS, Walmart Pharmacy, and Smith's (Kroger), carry empagliflozin 10 mg and 25 mg tablets. Presbyterian Hospital pharmacies in Albuquerque and Rust Medical Center pharmacies in Rio Rancho stock both doses. For rural patients in communities like Clovis, Farmington, or Silver City, mail-order pharmacies licensed to ship to New Mexico (including Optum Rx, Express Scripts, and Amazon Pharmacy) typically deliver within 3 to 5 business days.

503A compounding pharmacies licensed by the New Mexico Board of Pharmacy may compound empagliflozin for patients with documented need for a non-commercially available strength or formulation, such as a liquid suspension for patients with swallowing difficulties. However, compounded empagliflozin is not bioequivalent-tested against Jardiance, and the FDA has not designated empagliflozin as a drug in shortage, meaning 503A compounding is legally permitted only for individualized patient needs, not as a cost-reduction strategy [13]. Patients should verify that any compounding pharmacy holds an active New Mexico 503A license before filling.

The New Mexico Board of Pharmacy maintains a publicly searchable license database at nmbon.hsc.unm.edu (the regulatory body for pharmacy in the state), and out-of-state mail pharmacies must hold a non-resident pharmacy permit issued by New Mexico to legally ship prescriptions into the state [14].

Clinical Evidence Supporting Empagliflozin Across Its Three Indications

The evidence base for empagliflozin is broad and well-replicated, spanning three major indication categories.

For type 2 diabetes, EMPA-REG OUTCOME (N=7,020) established cardiovascular benefit on top of glucose lowering [2]. Mean HbA1c reduction with empagliflozin 10 mg was approximately 0.54% versus placebo at 206 weeks [2]. The drug also produced modest but consistent weight loss averaging 2.0 to 3.0 kg and a systolic blood pressure reduction of roughly 4 mmHg versus placebo, as reported in the trial's supplementary analyses published on PubMed [2].

For heart failure, the EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the primary composite of cardiovascular death or hospitalization for heart failure by 25% (hazard ratio 0.75; 95% CI 0.65 to 0.86; P<0.001) in patients with HFrEF, with results consistent across patients with and without diabetes [15]. The EMPEROR-Preserved trial (N=5,988) extended this benefit to HFpEF, showing a 21% relative risk reduction in the same composite endpoint (hazard ratio 0.79; 95% CI 0.69 to 0.90; P<0.001) [16].

For chronic kidney disease, EMPA-KIDNEY (N=6,609) published in 2023 confirmed a 28% reduction in kidney disease progression or cardiovascular death versus placebo (P<0.001), and this benefit extended to patients with eGFR as low as 20 mL/min/1.73m² [7]. The trial enrolled patients with and without type 2 diabetes, making empagliflozin one of the few agents with proven benefit across the full CKD spectrum regardless of glycemic status.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in CKD states: "We recommend empagliflozin for patients with type 2 diabetes and CKD who are already receiving the maximum tolerated dose of an ACE inhibitor or ARB" (Grade 1A) [17]. That guideline language is directly quotable in prior authorization documentation.

Transferring an Existing Jardiance Prescription to New Mexico

Patients relocating to New Mexico or temporarily residing in the state can transfer an existing Jardiance prescription from an out-of-state pharmacy to a New Mexico pharmacy. Under federal law (21 CFR Part 1306), non-controlled drug prescriptions may be transferred between pharmacies, though the original pharmacy must cancel its record of the remaining refills upon transfer [18]. Most retail chains (CVS, Walgreens, Walmart) allow chain-wide transfers without requiring a new prescription.

If a patient's existing out-of-state prescriber is not licensed in New Mexico, the prescription remains valid for the remaining authorized refills, but refills beyond the original authorization require a New Mexico-licensed prescriber. For patients who have relocated permanently, establishing care with a New Mexico provider, including a telehealth provider licensed in the state, within 60 to 90 days ensures uninterrupted access.

Mail-order pharmacies with valid New Mexico non-resident pharmacy permits can continue to fill refills from an out-of-state prescription provided the prescriber has active authority in their home state [18]. Patients should confirm their mail pharmacy holds this permit before assuming ongoing delivery is legal.

Managing Side Effects and Follow-Up After Starting Jardiance in New Mexico

Empagliflozin carries an FDA boxed warning regarding genital mycotic infections, euglycemic diabetic ketoacidosis (DKA) in certain at-risk patients, and lower-limb amputation risk in patients with severe peripheral arterial disease [3]. Post-prescription follow-up should include a repeat BMP at 4 to 6 weeks to recheck eGFR, as a transient decline of 5 to 10% in eGFR is expected and is not a reason to discontinue therapy in most patients [17].

The FDA label specifically instructs prescribers to hold empagliflozin at least 3 days before any surgical procedure or prolonged fasting to reduce DKA risk [3]. Telehealth providers in New Mexico should include this instruction in post-prescription patient education materials.

Patients in New Mexico with diabetes who also take insulin or sulfonylureas should be counseled that adding empagliflozin may require a 10 to 20% reduction in insulin dose to avoid hypoglycemia, consistent with guidance from the American Diabetes Association [6]. The ADA notes: "When an SGLT2 inhibitor is added to insulin therapy, a dose reduction of insulin may be necessary to reduce the risk of hypoglycemia" [6].

A repeat HbA1c at 3 months confirms glycemic response. Repeat UACR at 6 to 12 months documents renoprotective effect. Telehealth platforms serving New Mexico patients typically automate these follow-up lab orders at the time of the initial prescription, reducing the burden on patients to self-initiate testing.